To determine the safety and efficacy of collagen matrix as a patch Purpose: graft in glaucoma drainage surgery. Collagen matrix grafts may be advantageous because they do not need to be harvested from human donors.
Introduction
The use of glaucoma drainage implants to treat difficult glaucoma cases has increased in the past two decades 1 . These devices drain aqueous through a silicone tube to a reservoir plate covered by Tenon's capsule and conjunctiva. The tube is then covered by one of several materials to prevent exposure to the overlying conjunctiva. Although most complications are transient and self-limited, glaucoma drainage procedures carry the risk of persistent corneal edema, tube erosion, endophthalmitis/blebitis, and tube migration, among other complications 2 . Tube shunts in particular carry the risk of patch graft thinning and exposure of the subconjunctival portion of the shunt tube, which is a risk factor for infectious endophthalmitis 3, 4 . Prompt identification and revision of exposed patch grafts with collagenous human autograft or allograft material is therefore recommended 5 .
Several patch graft materials have been used. These include pericardium, fascia lata, cornea, sclera, and amniotic membrane 6,7 . Ologen (Aeon Astron Europe BV, Leiden, the Netherlands) is a porcine-derived biodegradable collagen matrix implant which has been studied and used as an adjunct to trabeculectomy 8, 9 . A recent case report showed successful use of Ologen as a patch before closing the conjunctiva in a case of tube erosion 10 . To our knowledge, Ologen has not been used as a primary patch graft in glaucoma tube shunt procedures. Collagen matrix may be advantageous because it does not need to be harvested from human donors and is less expensive than other patch graft materials. This is particularly important considering that Medicare (the federal health insurance program for people who are 65 or older, medicare.gov) now no longer reimburses for any patch graft material when combined with a tube shunt procedure (former CPT code 67255). Additionally, Ologen appears clear under the conjunctiva and provides improved cosmesis compared to other patch grafts ( Figure 1 , printed with permission courtesy of Steven R. Sarkisian, jr.). The purpose of this study was to determine the safety and efficacy of collagen matrix as a patch graft in glaucoma tube shunt surgery.
Materials and methods
This study was approved and monitored by the Institutional Review Board at the University of Oklahoma Health Science Center (IRB# 3425; reference #652312). Permission to publish clinical details and images was obtained for each subject. Potential subjects were identified by reviewing case logs of a single attending surgeon (S.R.S.). Charts of consecutive patients undergoing glaucoma tube shunt surgery with placement of collagen matrix patch graft between July 2009 and December 2010 were reviewed. Char were excluded if the patient had less than 12 months of followup data. Forty-three eyes of 40 patients were identified. Demographic and clinical information of the patients is listed in Table 1 . The primary outcome measure of this study was post-operative tube exposure requiring revision. 
Surgical technique
The glaucoma drainage implant of choice was placed in the usual fashion 11 . Once the tube was secured to the sclera, the collagen patch graft was used to cover the tube (Figure 2) . The Ologen to cover a tube comes as a 10×10×2 mm sheet. Presoaking the collagen is not necessary and is, in fact discouraged because once wet, the collagen becomes difficult to cut and can tear easily. While dry, the collagen sheet was cut to size to cover the tube per the surgeon's preference. Although some surgeons may desire to suture the collagen in place, we find this unnecessary as the collagen quickly picks up moisture from the scleral bed, does not slide out of place easily and never moves post-operatively once the conjunctiva is closed. However, great care is taken to ensure that the collagen is fully covered and the conjunctiva covering it is not under tension. Every effort must be made to be certain there is no chance that any part of the collagen is exposed and the conjunctiva is well secured. Once the conjunctiva was closed, a small amount of saline was placed in the anterior chamber and a fluorescein strip was used to verify the absence of leakage. Table 2 Collagen matrix patch graft data are provided in a spreadsheet. Description of the dataset is provided in the text file.
Results

A brief summary of results is displayed in
Discussion
To our knowledge, no study has investigated the use of collagen matrix material as a primary patch graft in glaucoma tube shunt surgery. Previous studies have reported rates of patch graft erosion. Gedde et al. reported tube erosion in five of 107 eyes (4.6%) in the tube versus trabeculectomy study at 5 years of follow-up 11 . In a study of 702 patients, Levinson et al. reported an exposure rate of 5.8% at a mean follow up of 36 months 12 . Additionally, Muir et al. reported an exposure rate of 6.2% in 1073 patients followed for an average of 41 months 13 . The erosion rate in our study, 4.7%, is comparable to these previous studies.
Several factors may predispose patients to patch graft erosion. In a cohort study of 121 eyes, Koval et al. identified Hispanic ethnicity, neovascular glaucoma, previous trabeculectomy, and combined surgery as potential risk factors for tube shunt exposure 14 . In the aforementioned study by Muir et al., female gender and white race were associated with an increased risk of graft exposure. Uveitis, diabetes, and type of tube shunt were not associated with increased risk 13 . Mechanical and immunologic factors may also contribute to graft erosion 15 . Both of the patients with graft erosion in our study had histories suggestive of poor wound healing and/or ocular inflammation. One had long-standing diabetes mellitus without a diagnosis of neovascular glaucoma. The second patient with erosion in our study had a history of iritis.
Ologen encapsulates when not exposed to aqueous and does not biodegrade. It is possible that the patch graft erosions in our study occurred because the Ologen was exposed and not well-covered initially, leading to patch melting. Care must be taken to not use Ologen if the conjunctiva is under tension when it is closed.
There are several limitations to this study. First, given its relatively small sample size and limited duration, further studies are necessary to determine the safety and efficacy of Ologen collagen matrix patch grafts compared to other commonly used materials. There are inherent limitations in a retrospective chart review, including lack of randomization of patients, lack of comparative control group and incomplete follow-up by patients not reviewed for this study. A prospective, large, controlled study is needed to compare erosion rates of Ologen to other graft materials. It is possible that collagen matrix patch grafts may be used successfully in glaucoma tube shunt surgery. They may be advantageous because they do not need to be harvested from human donors, are less expensive, and provide improved cosmesis compared to other commonly used materials. Further study is required to evaluate the longterm use of Ologen as a patch graft.
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The limitations of the study include its retrospective nature and the lack of a control arm. A greater number of patients would include the power of the study, and any future reports on this topic would do well to include more patients. The authors provide adequate support from the literature that a roughly 5% tube erosion rate, as was seen in this study, is the standard.
Another limitation of this study relates to the fact that there is a growing body of evidence that glaucoma tube shunt surgery may be safely performed without the use of any patch graft material. Using a long scleral tunnel needle technique, Oscar Albis and colleagues reported a 0% erosion rate in 106 Mexican children followed after Ahmed valve placement with no patch graft. The mean follow up was just over two years, no patients were followed for less than six months and some were followed for up to eight years. While this data is encouraging, the reality of the situation is that in the United States, many surgeons are still using patch graft materials, and these materials do have problems, cosmesis and cost being among them. I applaud the authors for making a valuable contribution to the surgical literature and for answering a straightforward but important question: is it reasonable to substitute collagen matrix for other graft materials in glaucoma drainage device surgery? Yes. No competing interests were disclosed. "The Use of Collagen Matrix As a Patch Graft in Glaucoma" is a well designed study on the use of Ologen as a primary graft in glaucoma shunt surgery. The title is appropriate, though it may benefit from the inclusion of the word "primary" (..."as a primary patch graft") to distinguish it from other publications on the use of Ologen as a patch graft. The method and analysis are well explained.
Although not the primary intent of the study, additional statistical analysis would be useful. This would include reporting the mean change in IOP and medication use post-operatively. While we do not expect that grafts would affect IOP or medication use, data showing IOP reductions could be useful in drawing this conclusion. Reporting the number of previous surgeries on the study eyes and eyelids may elucidate root causes for complications. At present, the supplemental data included only describes surgeries and procedures that occurred after the initial tube placement.
The conclusions are sensible and justified; however, they do not address whether use of Ologen in any way alters the mechanics of the glaucoma surgery and subsequent IOP management -which again we do not expect. Furthermore, this study describes the use and results of Ologen in one surgeon's hands. It is possible that results could be different in alternative surgical techniques that may differ in tunnel length and closure.
As identified by the authors in the discussion, the major limitations of this paper are its small study size and its lack of comparison to other grafts. However it does present a novel method for covering tubestimely given the shift of glaucoma to a surgical disease. This article serves as a straightforward and succinct study that justifies further investigation and a more robust sub-group analysis.
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